Forest Laboratories
Also known as: Forest Hills Lab | Forest Laboratories | FOREST LABS | FOREST LABS INC | FOREST LABS LLC | FOREST PHARMS | Forest Research Institute, a subdisiary of Forest Laboratories, Inc. | Forest Research Institute, a subsidiary of Forest Laboratories | Forest Research Institute, a subsidiary of Forest Laboratories Inc | Forest Research Institute, a subsidiary of Forest Laboratories Inc. | Forest Research Institute, a subsidiary of Forest Laboratories, Inc. | Forest Research Institute, a Subsidiary of Forest Laboratories Inc. | Forest Research Institute, a Subsidiary of Forest Laboratories, Inc. | Forest Research Institute Inc., A Subsidiary of Forest Laboratories | Forest Research Institute, Inc., a Subsidiary of Forest Laboratories, Inc. | Forest Research Institute Inc., A Subsidiary of Forest Laboratories Inc | Forest Research Institute, Inc.- A Subsidiary of Forest Laboratories, Inc.
Highest phase reached
Phase 4
First clinical trial
Sep 1, 2000First marketed drug
Jan 1, 1954First NDA
Jun 12, 1959Last known activity
Nov 1, 2023
Timeline
1950s
- Jun 8, 1951
epinephrine— NDA Secondary Org
- Jan 1, 1954
Forest Laboratories— Founded
- Jun 12, 1959
propiolattone— NDA Organization
2010s
- Apr 13, 2011
Clinical Data, Inc.— Acquired
- Feb 3, 2014
Aptalis— Acquired
- Jul 1, 2014
Actavis— Acquired By
- Jul 3, 2014
Furiex— Acquired
- Jun 26, 2019
AbbVie— Now
Drugs by trial phase (98 distinct, 351 trials)
Phase 4 (23 own, 2 via acquisition)
Phase 3 (31 own, 14 via acquisition)
Phase 2 (15 own, 9 via acquisition)
Phase 1 (2 own, 1 via acquisition)
Other trials (1 own, 0 via acquisition)
Indications
Approved for
- Alzheimer Disease
- Anxiety Disorders
- Asthma
- Bipolar Disorder
- Bronchial Spasm
- Bronchitis, Chronic
- Constipation
- Dementia
- Emphysema
- Fibromyalgia
- Hypertension
- Intraabdominal Infections
- Irritable Bowel Syndrome
- Major Depressive Disorder
- Pulmonary Disease, Chronic Obstructive
- Pyelonephritis
- Schizophrenia
- Urinary Tract Infections
Studied for
- Alcoholism
- Alzheimer Disease
- Amyotrophic Lateral Sclerosis
- Angina Pectoris
- Anxiety Disorders
- Anxiety, Separation
- Aphasia, Primary Progressive
- Arrhythmias, Cardiac
- Arthritis
- Arthritis, Infectious
- Arthritis, Rheumatoid
- Asperger Syndrome
- Asthma
- Asthma, Exercise-Induced
- Atrial Fibrillation
- Autism Spectrum Disorder
- Autistic Disorder
- Back Pain
- Bacteremia
- Bacterial Infections
- Behavior, Addictive
- Binge-Eating Disorder
- Bipolar Disorder
- Brain Injuries
- Brain Injuries, Traumatic
- Bulimia
- Cardiovascular Diseases
- Cellulitis
- Child Development Disorders, Pervasive
- Chronic Pain
- Cognition Disorders
- Cognitive Dysfunction
- Communicable Diseases
- Compulsive Personality Disorder
- Constipation
- Coronary Artery Disease
- Coronary Disease
- Cystic Fibrosis
- Delirium
- Dementia
- Depression
- Depression, Postpartum
- Depressive Disorder
- Developmental Disabilities
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Diabetic Neuropathies
- Diarrhea
- Disease
- Disruptive, Impulse Control, and Conduct Disorders
- Down Syndrome
- Dyspepsia
- Dyssomnias
- Dysthymic Disorder
- Emergencies
- Eosinophilic Esophagitis
- Epilepsy
- Epilepsy, Temporal Lobe
- Erectile Dysfunction
- Esophagitis
- Essential Tremor
- Exocrine Pancreatic Insufficiency
- Facial Pain
- Facies
- Fatigue
- Febrile Neutropenia
- Feeding and Eating Disorders
- Fever
- Fibromyalgia
- Fibrosis
- Fissure in Ano
- Fractures, Bone
- Fractures, Open
- Frontotemporal Dementia
- Frontotemporal Lobar Degeneration
- Gambling
- Gastroparesis
- Glucose Intolerance
- Heartburn
- Heart Diseases
- Heart Failure
- Helicobacter Infections
- Hemorrhage
- Huntington Disease
- Hyperalgesia
- Hypertension
- Hypertension, Portal
- Infections
- Intraabdominal Infections
- Irritable Bowel Syndrome
- Joint Diseases
- Leiomyoma
- Low Back Pain
- Lung Diseases
- Lung Diseases, Obstructive
- Lupus Erythematosus, Systemic
- Major Depressive Disorder
- Memory Disorders
- Mental Disorders
- Motor Neuron Disease
Marketed drugs (37)
Subsidiaries (4 direct, 7 total across the full acquisition tree)
Recent trials (50)
- NCT05931484Lead sponsorPhase 2Nov 1, 2023
- NCT05938452Lead sponsorPhase 1Dec 12, 2022
- NCT03593213Lead sponsorPhase 3Jul 30, 2018
- NCT03573297Lead sponsorPhase 3Jun 15, 2018
- NCT02720198CollaboratorPhase 3Jan 23, 2017
- NCT02937181CollaboratorPhase 4Dec 1, 2016
- NCT02600793CollaboratorPhase 1Aug 1, 2016
- NCT02732327Lead sponsorPhase 2May 1, 2016
- NCT02670538Lead sponsorPhase 3Mar 1, 2016
- NCT02670551Lead sponsorPhase 3Mar 1, 2016
- NCT02634437Lead sponsorPhase 1Dec 1, 2015
- NCT02559817Lead sponsorPhase 2Nov 1, 2015
- NCT02590432Lead sponsorPhase 4Nov 1, 2015
- NCT02559570Lead sponsorPhase 2Nov 1, 2015
- NCT02559206CollaboratorPhase 2Oct 1, 2015
Details
- Founded
- New York, NY, US Jan 1, 1954
- First NDA
- Jun 12, 1959
- Last known activity
- Nov 1, 2023
Designations held
- Fast track
- Priority review
Notes
On July 1, 2014, the company was acquired by Actavis (now Allergan). https://en.wikipedia.org/wiki/Forest_Laboratories